Exploring the Potential Applications of EIF3M (Hfl-B5) as a Drug Target or Biomarker

Target Name: EIF3M

NCBI ID: G10480

EIF3M

Exploring the Potential Applications of EIF3M (Hfl-B5) as a Drug Target or Biomarker

The identification and characterization of potential drug targets and biomarkers is a crucial step in the development of new pharmaceuticals. One of the promising targets in the field of cancer research is the protein EIF3M (endoplasmic reticulum-associated protein 3M), also known as Hfl-B5. EIF3M is a protein that is expressed in various cell types, including cancer cells, and has been associated with various cellular processes, including cell signaling, protein transport, and intracellular signaling.

The Protein EIF3M (Hfl-B5)

EIF3M is a 22-kDa protein that is expressed in various cell types, including cancer cells. It is highly conserved and has been shown to be involved in various cellular processes, including cell signaling, protein transport, and intracellular signaling. EIF3M is a component of the endoplasmic reticulum (ER) and is highly expressed in the cytoplasm of cancer cells.

Function and Interaction

EIF3M is involved in various cellular processes, including cell signaling, protein transport, and intracellular signaling. One of the well-documented functions of EIF3M is its role in cell signaling. EIF3M has been shown to be involved in several signaling pathways, including the PI3K/Akt signaling pathway, the NF-kappa signaling pathway, and the NF-kappa-B signaling pathway.

In addition to its role in cell signaling, EIF3M is also involved in protein transport. EIF3M has been shown to be a protein that is targeted to the endoplasmic reticulum (ER) and is involved in the delivery of various proteins to the ER. This function of EIF3M is important for the regulation of protein function and for the development of drug targets.

EIF3M is also involved in intracellular signaling. EIF3M has been shown to be involved in the regulation of various cellular processes, including cell growth, apoptosis, and cell cycle progression.

Drug Target Potential

The potential drug targets for EIF3M are numerous. One of the most promising targets is the inhibition of EIF3M function, as this has been shown to have therapeutic effects in various cellular processes. The inhibition of EIF3M function has been shown to result in the inhibition of various cellular processes, including cell signaling, protein transport, and intracellular signaling.

In addition to its role in cellular processes, EIF3M is also a potential biomarker for cancer. The expression of EIF3M has been shown to be associated with the development and progression of various types of cancer, including breast, ovarian, and prostate cancer.

Biomarker Potential

The potential use of EIF3M as a biomarker for cancer is significant. The expression of EIF3M has been shown to be associated with the development and progression of various types of cancer, including breast, ovarian, and prostate cancer. This suggests that EIF3M may be a useful biomarker for the diagnosis and prognosis of cancer.

In addition to its potential as a biomarker, EIF3M may also be a useful drug target. The inhibition of EIF3M function has been shown to have therapeutic effects in various cellular processes, including cell signaling, protein transport, and intracellular signaling. This suggests that EIF3M may be a potential drug target for the treatment of various types of cancer.

Conclusion

In conclusion, EIF3M is a protein that is involved in various cellular processes, including cell signaling, protein transport, and intracellular signaling. The potential drug targets and biomarkers for EIF3M are numerous and continue to be explored in the field of cancer research. Further studies are needed to fully understand the role of EIF3M in

Protein Name: Eukaryotic Translation Initiation Factor 3 Subunit M

Functions: Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein synthesis (PubMed:17403899, PubMed:25849773, PubMed:27462815). The eIF-3 complex associates with the 40S ribosome and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-tRNAi and eIF-5 to form the 43S pre-initiation complex (43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for disassembly and recycling of post-termination ribosomal complexes and subsequently prevents premature joining of the 40S and 60S ribosomal subunits prior to initiation (PubMed:17403899). The eIF-3 complex specifically targets and initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-loop binding to exert either translational activation or repression (PubMed:25849773)

The "EIF3M Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF3M comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets